NCT02927964View on ClinicalTrials.gov

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 7, 2016

Primary Completion Date

May 18, 2023

Study Completion Date

May 18, 2023

Conditions

Grade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaRecurrent Follicular LymphomaRefractory Follicular LymphomaMantle Cell LymphomaMarginal Zone Lymphoma

Interventions

DRUG

Ibrutinib

Given PO

RADIATION

Radiation Therapy

Undergo radiation therapy

DRUG

TLR9 Agonist SD-101

Given IT

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors

collaborator

Janssen, LP

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

The Leukemia and Lymphoma Society

OTHER

collaborator

Rising Tide Foundation

OTHER

lead

Robert Lowsky

OTHER

NCT02927964 - TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | Biotech Hunter | Biotech Hunter